News

The 7th PROFID General Assembly Meeting was held on 5 July 2023 in Berlin. After a long period of web meetings due to the COVID-19 pandemic, it was the first face-to-face meeting after the project kick-off event in 2020. All work package leaders presented the current status of their work. In addition, the start of …

We had the great opportunity to present PROFID to world-leading cardiology experts at the EHRA Congress 2023 in Barcelona. Gerhard Hindricks gave a presentation about the “Generation of novel randomized evidence for the role of primary prevention ICD under contemporary treatment”, in which he showed once again why the PROFID project is urgently needed for the improvement of patient care.

In a news article released in March 2023, Dr. Nikolaos Dagres and Prof. Gerhard Hindricks, chief investigators and coordinators of the PROFID project, present new strategies in order to reassess the role of routine prophylactic defibrillator implantation for primary prevention of SCD.

After extensive 2.5 years, the PROFID data analysis has been completed. The results, which were presented at the ESC Congress 2022 in Barcelona, have significant implications for the setup of the randomized trial programme. We are currently finalizing an updated design of the PROFID clinical trial, in order to start the submissions to the Ethics Committees at the beginning of 2023.

The Clinical Research Institute in Munich, Germany, is a full-service Contract Research Organisation (CRO) specialized in large international, commercial and non-commercial (academic) clinical studies in Europe covering both, drug trials and medical device studies.

This year, PROFID had a marked presence at the European Society of Cardiology 2022 Congress, the world’s largest cardiovascular congress, during the session “Latest Science in Arrhythmias”. Project coordinator Dr. Nikolaos Dagres of the Leipzig Heart Institute presented the final results of the PROFID analysis.

The European Association of Cardiology (ESC) is an independent, non-profit organisation and represents more than 95,000 decision-makers and healthcare professionals in the field of cardiology. The ESC acts in the interest of patients by providing cardiologists with the support and tools they need to deliver the best possible care.

In phase one of the development of the PROFID risc prediction model we analysed 19 datasets from Europe, Israel and the US, based on a collection of existing highly phenotyped data with the largest number of post-MI patients (~225,000 observations).